Your browser doesn't support javascript.
loading
Cerebellopontine angle meningiomas: LINAC stereotactic radiosurgery treatment.
Ortiz García, Isabel M; Jorques Infante, Ana M; Cordero Tous, Nicolás; Almansa López, Julio; Expósito Hernández, José; Olivares Granados, Gonzalo.
Afiliação
  • Ortiz García IM; Neurocirugía, Hospital Universitario Virgen de las Nieves, Granada, Spain. Electronic address: isabelmortizg@gmail.com.
  • Jorques Infante AM; Neurocirugía, Hospital Universitario Virgen de las Nieves, Granada, Spain.
  • Cordero Tous N; Neurocirugía, Hospital Universitario Virgen de las Nieves, Granada, Spain.
  • Almansa López J; Servicio de Radiofísica, Hospital Universitario Virgen de las Nieves, Granada, Spain.
  • Expósito Hernández J; Oncología Radioterápica, Hospital Universitario Virgen de las Nieves, Granada, Spain.
  • Olivares Granados G; Neurocirugía, Hospital Universitario Virgen de las Nieves, Granada, Spain.
Neurocirugia (Astur : Engl Ed) ; 34(6): 283-291, 2023.
Article em En | MEDLINE | ID: mdl-36842609
ABSTRACT

OBJECTIVES:

To evaluate the efficacy of treatment with linear accelerator-based stereotactic radiosurgery (LINAC) in cerebellopontine angle meningiomas.

METHODS:

We analyzed 80 patients diagnosed with cerebellopontine angle meningiomas between 2001 and 2014, treated with stereotactic radiosurgery (SRS), of whom 81.9% (n=68) were women, with an average age of 59.1 years (32-79). SRS was applied as primary treatment in 83.7% (n=67) and in 16.3% (n=13) as an adjuvant treatment to surgery. SRS treatment was provided using LINAC (Varian 600, 6MeV) with M3 micromultilamines (brainLab) and stereotactic frame. The average tumor volume was 3.12cm3 (0.34-10.36cm3) and the coverage dose was 14Gy (12-16Gy). We performed a retrospective descriptive analysis and survival analysis was performed with the Kaplan-Meier method and multivariate analysis to determine those factors predictive of tumor progression or clinical improvement.

RESULTS:

After an average follow-up period of 86.9 months (12-184), the tumor control rate was 92.8% (n=77). At the end of the study, there was an overall reduction in tumor volume of 32.8%, with an average final volume of 2.11cm3 (0-10.35cm3). The progression-free survival rate at 5, 10 and 12 years was 98%, 95% and 83.3% respectively. The higher tumor volume (p=0.047) was associated with progression. There was clinical improvement in 26.5% (n=21) of cases and clinical worsening in 16.2% (n=13). Worsening is related to the radiation dose received by the brainstem (p=0.02). Complications were 8.7% (7 cases) of hearing loss, 5% (4 cases) of brain radionecrosis, and 3.7% (3 cases) of cranial nerve V neuropathy. Hearing loss was related to initial tumor size (p=0.033) and maximum dose (p=0.037). The occurrence of radionecrosis with the maximum dose (p=0.037).

CONCLUSIONS:

Treatment of cerebellopontine angle meningiomas with single-dose SRS using LINAC is effective in the long term. Better tumor control rates were obtained in patients with small lesions.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neuroma Acústico / Radiocirurgia / Perda Auditiva / Neoplasias Meníngeas / Meningioma Tipo de estudo: Prognostic_studies Limite: Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neuroma Acústico / Radiocirurgia / Perda Auditiva / Neoplasias Meníngeas / Meningioma Tipo de estudo: Prognostic_studies Limite: Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2023 Tipo de documento: Article